Sarah Gooding
@DrSarahGooding
Followers
408
Following
908
Media
1
Statuses
96
Clinician Scientist researching better treatment for myeloma, treating people with multiple myeloma @MRC_MHU @oxfordhaem #CRUKfunded
Joined December 2019
RT @DrJamKothari: I’m delighted to announce the launch of The Myeloma Minutes podcast , for all those affected by myeloma . Im co-hosting w….
themyelomaminutes.podbean.com
A living library of credible information for patients of multiple myeloma and their caregivers.
0
9
0
RT @MRC_WIMM: For International Women's Day tomorrow, we asked some of our women scientists, including @MiraKassouf & @DrSarahGooding, to r….
0
9
0
Take a look at this and let us know what you think! It’s been great working on this with you @AbAttacks #mmsm.
Good morning everyone, I'm pleased to share our latest advance in bone marrow in vitro modelling: .
0
0
1
RT @VJHemOnc: It's a lovely day here in Oxford at the beautiful Cheng Kar Shun Digital Hub in Jesus College, where Dr Karthik Ramasamy is k….
0
1
0
RT @VJHemOnc: We just interviewed the lovely @AnetaMikulasova (@UniofNewcastle), who shared insights into the use of multiomics for explori….
0
1
0
RT @VJHemOnc: Thank you to Abdullah Khan (@AbAttacks) of @MRC_WIMM for stopping by to discuss his work on engineering complex human pre-cli….
0
1
0
RT @VJHemOnc: It was fantastic to catch up with Prof. Jackson (@profghjackson) of @NewcastleHosps to hear about the state of clinical #myel….
0
1
0
RT @VJHemOnc: It is always a pleasure to speak with Karthik Ramasamy, an organizer of the Oxford Myeloma Workshop!😁. Dr Ramasamy stopped by….
0
1
0
RT @VJHemOnc: Wrapping up day 1 at the Oxford Myeloma Workshop with a joint interview w/ @RascheLeo and Neils Weinhold, who discussed their….
0
3
0
RT @VJHemOnc: A fantastic start to the second day of the Oxford Myeloma Workshop with a talk from Paul Richardson (@DanaFarber) on approach….
0
2
0
RT @DrRakeshPopat: DREAMM-7 demonstrating a clear survival benefit for Bela-Vd compared to Dara-Vd. Very important to get the right Belama….
0
16
0
RT @graham74GC: More jobs in Oxford! Are you an SpR or more junior doc with a keen interest in haematology and interested in clinical resea….
0
12
0
Congratulations on getting this to publication @ovanoekelen.
Today, an important part of my PhD work was published in @CellRepMed! In a huge collaborative effort (2 papers published back to back) we took a deep dive into the mechanism of action of the novel CELMoD iberdomide for patients with multiple #myeloma #mmsm.
0
0
2
RT @AbAttacks: Morning everyone! Pleased to share a detailed protocol of our bone marrow organoid approach in @NatureProtocols :. https://t….
nature.com
Nature Protocols - This protocol can be used to generate three-dimensional vascularized bone marrow organoids from human induced pluripotent stem cells. The organoids contain key stromal and...
0
28
0
RT @AdamCribbs: New paper from our group: we show that PCR, not sequencing, is the main source of error in bulk and single-cell expts and w….
nature.com
Nature Methods - This study introduces a method utilizing homotrimeric nucleotide blocks to achieve accurate counts of RNA molecules in both bulk and single-cell sequencing data.
0
122
0
RT @DrRakeshPopat: UK Myeloma Research Alliance away day group photo!📸.A superb day debating all aspects of myeloma from smouldering to rel….
0
8
0
RT @CRUKresearch: 💭Can we learn the lessons of the personalised medicine revolution in solid cancers to improve treatment of multiple myelo….
0
7
0
RT @Chapman_lab_UK: Our lab's latest is now out on BioRxiv. In this work we set out to understand how 'shieldin' regulates #DNArepair, focu….
biorxiv.org
53BP1 regulates DNA end-joining in lymphocytes, diversifying immune antigen receptors. This involves nucleosome-bound 53BP1 at DNA double-stranded breaks (DSBs) recruiting RIF1 and shieldin, a poorly...
0
27
0
Brilliantly clear @GauravA_UK.
Stellar presentation by @GauravA_UK from @OxfordHaem. Good to see the MGP NGS panel moving to the clinic! Congratulations @DrSarahGooding in leading this study!
1
1
25
RT @beth_psaila: Come join us! We are recruiting an RA to support our work understanding blood cancer development and testing new therapies….
0
20
0